Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lamellar cystic fibrosis drug gets ODD from EC
The company has developed LMS-611 from its proprietary inhaled Lamellasome delivery platform. With this milestone, the company expects to get investment and development partners for advancing the drug
The company has developed LMS-611 from its proprietary inhaled Lamellasome delivery platform. With this milestone, the company expects to get investment and development partners for advancing the drug
The GLP certification has been granted under the 2004/9/EU directive (safety testing) by the French Health and Safety Agency (Agence Francaise de Securite Sanitaire des Produits de Sante
Istodax is an epigenetic therapy and a member of a class of cancer drugs known as histone deacetylase (HDAC) inhibitors. The approval has been granted for the product
The trial is intended to evaluate the impact of bardoxolone methyl on time to important clinical outcomes. The companies expect to recruit around 16,00 patients in the trial
The facility will be constructed in the Novoorlovskaya Special Economic Zone (SEZ), located to the north of the St. Petersburg city center. Once completed and approved for commercial
Cebix will recruit around 30-60 patients in the trial. Earlier, in preclinical trials, Ersatta has demonstrated improved nerve function in a rat diabetic neuropathy model. The company intends
HEOS is a drug research information management software platform that provides a secure, user-friendly data handling system and allows collaborators to view results and make informed decisions. Powered
Boehringer obtains development and commercialisation rights to ZP2929 – Zealand Pharma’s glucagon/GLP-1 dual agonist drug candidate. Under the agreement, Zealand Pharma will be responsible for conducting the first
The trial results demonstrated that the vaccine was safe and well tolerated through out the study which involved around 200 healthy volunteers. The vaccine, when used in combination
Tripos’ molecular modeling software portfolio will be used for target identification, lead identification and leadoptimization. Moulder Center director Magid Abou-Gharbia said that it has set up a laboratory